Combination of a Proteomics Approach and Reengineering of Meso Scale Network Models for Prediction of Mode-of-Action for Tyrosine Kinase Inhibitors

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

(2012) H. J. Khoury et al.   BLOOD

Peroxiredoxins 3 and 4 Are Overexpressed in Prostate Cancer Tissue and Affect the Proliferation of Prostate Cancer Cells in Vitro

(2012) Ramesh Ummanni et al.   JOURNAL OF PROTEOME RESEARCH

Proteomic Profiling of Germ Cell Cancer Cells Treated with Aaptamine, a Marine Alkaloid with Antiproliferative Activity

(2012) Sergey A. Dyshlovoy et al.   JOURNAL OF PROTEOME RESEARCH

Combinatorial drug therapy for cancer in the post-genomic era

(2012) Bissan Al-Lazikani et al.   NATURE BIOTECHNOLOGY

Expression of Eukaryotic Initiation Factor 5A and Hypusine Forming Enzymes in Glioblastoma Patient Samples: Implications for New Targeted Therapies

(2012) Michael Preukschas et al.   PLoS One

Predicting drug side-effect profiles: a chemical fragment-based approach

(2011) Edouard Pauwels et al.   BMC BIOINFORMATICS

A Novel Method of Transcriptional Response Analysis to Facilitate Drug Repositioning for Cancer Therapy

(2011) G. Jin et al.   CANCER RESEARCH

An Algorithmic Framework for Predicting Side Effects of Drugs

(2011) Nir Atias et al.   JOURNAL OF COMPUTATIONAL BIOLOGY

Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes

(2011) Thomas Force et al.   NATURE REVIEWS DRUG DISCOVERY

Identification of Candidate Small-Molecule Therapeutics to Cancer by Gene-Signature Perturbation in Connectivity Mapping

(2011) Darragh G. McArt et al.   PLoS One

Identification of Clinically Relevant Protein Targets in Prostate Cancer with 2D-DIGE Coupled Mass Spectrometry and Systems Biology Network Platform

(2011) Ramesh Ummanni et al.   PLoS One

Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data

(2011) M. Sirota et al.   Science Translational Medicine

Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data

(2011) Xing-Ming Zhao et al.   PLoS Computational Biology

Transglutaminase 2: a multi-functional protein in multiple subcellular compartments

(2010) Donghyun Park et al.   AMINO ACIDS

The Bcr–Abl kinase regulates the actin cytoskeleton via a GADS/Slp-76/Nck1 adaptor protein pathway

(2010) Christian Preisinger et al.   CELLULAR SIGNALLING

Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia

(2010) T. O'Hare et al.   CLINICAL CANCER RESEARCH

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib

(2010) Guoqing Wei et al.   Journal of Hematology & Oncology

Proteomics Analysis of Cellular Imatinib Targets and their Candidate Downstream Effectors

(2010) Susanne B. Breitkopf et al.   JOURNAL OF PROTEOME RESEARCH

Mass spectrometry in high-throughput proteomics: ready for the big time

(2010) Tommy Nilsson et al.   NATURE METHODS

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analysis of Compound Synergy in High-Throughput Cellular Screens by Population-Based Lifetime Modeling

(2010) Martin Peifer et al.   PLoS One

Predictive Mesoscale Network Model of Cell Fate Decisions during C. elegans Embryogenesis

(2009) David A. Winkler et al.   ARTIFICIAL LIFE

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

(2009) Thomas O'Hare et al.   CANCER CELL

Charting the molecular network of the drug target Bcr-Abl

(2009) M. Brehme et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia

(2009) Gunhild Keller et al.   Expert Review of Hematology

Identifying Drug Effects via Pathway Alterations using an Integer Linear Programming Optimization Formulation on Phosphoproteomic Data

(2009) Alexander Mitsos et al.   PLoS Computational Biology

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I

(2008) A. Gontarewicz et al.   BLOOD

Local identification of scalar hybrid models with tree structure

(2008) B. Fiedler et al.   IMA JOURNAL OF APPLIED MATHEMATICS

Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors

(2008) P. Ross-Macdonald et al.   MOLECULAR CANCER THERAPEUTICS

A modular approach for integrative analysis of large-scale gene-expression and drug-response data

(2008) Zoltán Kutalik et al.   NATURE BIOTECHNOLOGY

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY

Toxicities Associated with the Administration of Sorafenib, Sunitinib, and Temsirolimus and Their Management in Patients with Metastatic Renal Cell Carcinoma

(2007) Naeem Bhojani et al.   EUROPEAN UROLOGY